This sponsored supplement was produced by Focus Reports.
Project Director: Mariuca Georgescu
Journalist: Cameron Rochette
Contributors: Alina Manac & Emilie Laumond
Report Publisher: Ines Nandin
For exclusive interviews and more info, please log onto http://Pharma.FocusReports.net/ or write to firstname.lastname@example.org
COLOMBIA: Confidence in Uncertainty
Under the administration of President Juan Manuel Santos, Colombia is focusing on bolstering the commercial sector. Thanks
to the ratification of free trade agreements with 14 countries around the world since 2011, including the United States, foreign
direct investment reached a record high of COP 29 trillion (USD 16 billion) in 2012. While this is good news for the pharmaceutical
industry, there is still a strong debate about how healthcare in Colombia can be improved. While Colombia enjoys near-universal
coverage, a feat rarely seen in Latin America, the financial strain caused by this broad coverage has created the need for
change. The industry is watching as the country enters a period of transformation.
Código-Huella-Laberinto (Fingerprints) by Maria Ruiz, Courtesy of Janssen Colombia
"The title of your report is 'Confidence in Uncertainty'," remarked Alejandro Gaviria, Minister of Health and Social Protection
of Colombia, as he sipped a freshly brewed tinto coffee from his office in the historic Candelaria district of Bogotá. "Ultimately,
it is my goal to foster more confidence in the system and among all stakeholders in the health industry. Therefore, I hope
that your next report in Colombia will be called 'Confidence and Certainty.' Colombia is in an exciting state of change, and
the country has great potential as one of the most promising emerging markets in the world today."
Alejandro Gaviria, Minister of Health and Social Protection
Colombia has experienced economic improvement in recent years. Since 2010, the country has shown an average of 5.1 percent
growth in GDP, placing it well above the Latin American average. Colombia's trade balance increased from $24.6 billion in
2002 to $119.3 billion in 2012. The country's foreign currency rating was recently upgraded by credit agency Standard and
Poor's from BBB- to BBB, increasing the country's attractiveness for foreign direct investment (FDI). The country's debt to
GDP ratio has decreased from 40 percent in 2010 to 33 percent today.
Rafael Romero Piñeros, President Commission 7 – Chamber of Representatives
The pharmaceutical industry is no exception. Business Monitor International has estimated an increase in pharmaceutical sales
from COP 7.55 billion (USD 4.2 billion) in 2012 to COP 8.07 billion (USD 4.45 billion) in 2013, suggesting that there is growth
in Colombia, but at a rather slow rate. This may be indicative of potential but it is unclear if Colombia will experience
a surge anytime soon.
Blanca Elvira Cajigas, Director General INVIMA